MedTrace Logo

Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

NCT03666351 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2022-09-15

No results posted yet for this study

Summary

To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation between the intensive care group and the usual care group for patients with hypertension accompanied by aortic valve disease and evaluate an influence of blood pressure regulation on improvement of left ventricular hypertrophy and its safety

Conditions

  • Aortic Stenosis
  • Aortic Regurgitation
  • Hypertension
  • LVM
  • Left Ventricular Hypertrophy

Interventions

DRUG

Amlodipine 5mg

Amlodipine 5 mg

DRUG

Losartan

Losartan Potassium 50 mg

DRUG

Losartan and Amlodipine

Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg

DRUG

Amlodipine/Losartan/Chlorthalidone

Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg

DRUG

current treatment

treatment is done by maintaining the current treatment

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Duk-Hyun Kang · 10 institutions including Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-18
Primary Completion
2022-07-25
Completion
2022-07-25

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03666351 on ClinicalTrials.gov